Dementia

>

Latest News

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

February 20th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.
The Week in Review: February 12-16

February 17th 2024

dementia
Drug for Agitation in Alzheimer Disease Dementia Fails in Phase 3 Trial

February 14th 2024

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.
The Week in Review: February 5-9

February 10th 2024

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.
The Week in Review: January 29-February 2

February 3rd 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.